- The stock has surged over 2,500% since the end of April, attracting significant investor interest despite the absence of formal news or catalysts.
- RGC's explosive performance has outpaced the broader Nasdaq market, which only rose by approximately 0.4% on the same day.
- The biotech sector's volatility and speculative nature have made RGC a focal point for traders, raising questions about the sustainability of its rapid rise.
That right there of no real news that sparked it, would make me not stick around much longer as it is a China company.